516 results on '"de Mestier, Louis"'
Search Results
2. Outcome and survival were similar with laparoscopic and open pancreatectomy in 102 solid pseudopapillary neoplasms
3. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma
4. The Need for Centralization for Small Intestinal Neuroendocrine Tumor Surgery: A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study
5. ASO Visual Abstract: The Need of Centralization for Small Intestinal Neuroendocrine Tumor Surgery—A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study
6. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma
7. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1
8. Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors
9. Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN Study Group
10. Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin
11. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting
12. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
13. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome
14. Efficacy of treatments for VIPoma: A GTE multicentric series
15. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma
16. Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting
17. Are recist criteria adequate in assessing the response to therapy in metastatic NEN?
18. Endoscopic diagnosis and treatment of neuroendocrine tumors
19. Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors
20. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors
21. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
22. Abstract B064: Redefining phenotypic heterogeneity of pancreatic ductal adenocarcinoma: A bottom-up approach
23. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
24. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network
25. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach
26. Diagnostic challenges of pancreatic acinar cystic transformation: a single-centre retrospective study of 64 patients
27. Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting
28. The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs
29. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors
30. Absorbable Polyglactin vs. Non-Cross-linked Porcine Biological Mesh for the Surgical Treatment of Infected Incisional Hernia
31. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours
32. Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors
33. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)
34. Systematic Resection of the Visible Scar After Incomplete Endoscopic Resection of Rectal Neuroendocrine Tumors.
35. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
36. ASO Visual Abstract: The Need of Centralization for Small Intestinal Neuroendocrine Tumor Surgery—A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study
37. Systematic Resection of the Visible Scar After Incomplete Endoscopic Resection of Rectal Neuroendocrine Tumors
38. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines / Association Française de Chirurgie Endocrinienne / REseau NAtional de prise en charge des Tumeurs ENdocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1
39. High Tumor Uptake on18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d’étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network
40. Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN Study Group
41. Pancreas; Endocrine Tumors
42. Management and outcomes of carcinoid heart disease with liver metastases of midgut neuroendocrine tumours
43. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST
44. Management and outcomes of carcinoid heart disease with liver metastases of midgut neuroendocrine tumours.
45. High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network.
46. Prognostic Factors of Acinar Cell Carcinomas: A Study of 44 Patients
47. Une tumeur neuroendocrine pancréatique kystique bien spéciale
48. Unraveling Pancreatic Segmentation
49. Supplementary Tables from Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
50. Supplementary Figure 4 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.